‘Too high, too low’: The complexities of using thresholds in isolation to inform precautionary allergen (‘may contain’) labels

TY - JOUR

T1 - ‘Too high, too low’

T2 - The complexities of using thresholds in isolation to inform precautionary allergen (‘may contain’) labels

AU - the EAACI Taskforce on Food allergen thresholds

AU - Turner, Paul J.

AU - Baumert, Joseph L.

AU - Beyer, Kirsten

AU - Brooke-Taylor, Simon

AU - Comberiati, Pasquale

AU - Crevel, René W.R.

AU - Gerdts, Jennifer D.

AU - Hazel Gowland, M.

AU - Houben, Geert F.

AU - Hourihane, Jonathan O.B.

AU - Konstantinou, George N.

AU - La Vieille, Sébastien

AU - Moya, Beatriz

AU - Muraro, Antonella

AU - Mills, E. N.Clare

AU - Patel, Nandinee

AU - Podestà, Marcia

AU - Popping, Bert

AU - Reese, Imke

AU - Roberts, Graham

AU - Said, Maria

AU - Santos, Alexandra F.

AU - Schnadt, Sabine

AU - Taylor, Steve L.

AU - Vlieg-Boerstra, Berber

AU - Remington, Benjamin C.

N1 - Funding Information: NP and PJT are supported through The NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed in this article are those of the authors and do not necessarily reflect those of the NHS, NIHR, the UK Departments of Health or Health Canada. Funding Information: The following authors are members of the EAACI Taskforce on Food allergen thresholds: K Beyer, P Comberiati, G Konstantinou, ENC Mills, A Muraro, N Patel, B Remington, A Santos, S Schnadt, PJ Turner and B Vlieg‐Boerstra. The following authors were members of the FAO/WHO Ad hoc Expert Consultation on Risk Assessment of Food Allergens: J Baumert, S Brooke‐Taylor, R Crevel, G Houben, S La Vieille, ENC Mills, B Popping, B Remington, S Taylor and PJ Turner. Dr Turner reports personal fees from Aimmune Therapeutics, DBV Technologies, Allergenis, UK Food Standards Agency and ILSI Europe; grants from National Institute for Health Research (NIHR)/Imperial Biomedical Research Centre, UK Medical Research Council, UK Food Standards Agency, End Allergies Together and Jon Moulton Charity Trust, outside the submitted work. Dr Baumert reports personal fees from Neogen Corporation, outside the submitted work. Dr Beyer reports grants/research supports from Aimmune Therapeutics, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm and honoraria or consultation fees from Aimmune Therapeutics, Bencard, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, Jenapharma, Mylan/Meda, Nestle, Novartis and Thermo Fisher outside of the submitted work. Dr Brooke‐Taylor reports personal fees from The Allergen Bureau of Australia and New Zealand, outside the submitted work. Dr Crevel reports personal fees from Unilever Pensions, Food Allergy Research and Resource Program (University of Nebraska), Syngenta PLC, Upfield R&D BV, Zoetis LLC, Exponent Ltd., Fermentalg SA, CEV SA, ILSI‐Europe and other support from EAACI, outside the submitted work. Dr JO’B Hourihane receives research funding from NCRC Ireland, City of Dublin Skin and Cancer Hospital, Temple St Hospital Foundation, Clemens von Pirquet Foundation, Aimmune Therapeutics, DBV Technologies and Johnson& Johnson. He is an advisory board member for Aimmune Therapeutics and receives speaker fees from DBV Technologies. He is a board member of the Irish Association of Allergy and Immunology and the Irish Food Allergy Network, which receive unrestricted grants and logistical support from industry sources for educational activities. Dr Konstantinou reports speaker fees and honoraria from Novartis. Dr Mills reports grants and other support from Reacta Biotech Ltd., grants from the European Food Safety Authority, Food Standards Agency and other support from the Biological and Biotechnological Sciences Research Council, Medical Research Council and Innovate UK, outside the submitted work. In addition, Dr Mills has a patent on blinding of allergens in foods for oral food challenges pending and was a founder director of Reacta Biotech and a member of the board until November 2019; she owns founder shares in the company. Dr Muraro reports speaker fees from Aimmune Therapeutics, DBV and Nestlé Purina and is an advisory board member/fees from Regeneron IDMC. Dr Reese reports honoraria from AlbertZwei media GmbH, ALK‐Abello Arzneimittel GmbH, Beiersdorf Dermo Medical GmbH, InfectoPharm Arzneimittel und Consilium GmbH, Leo Pharma Gmbh, Nestlé Deutschland AG, Novartis Pharma GmbH, Nutricia Milupa GmbH and Sanomega GmbH outside of the submitted work. M. Said is Chief Executive Officer for Allergy & Anaphylaxis Australia, which reports grants from Bulla Family Dairy, Freedom Foods, Nestle, NSW Food Authority, Mondelez, Nutricia, Abbott and Sweet William, and non‐financial support from Nuts for Life, outside the submitted work. Dr Santos reports grants from Medical Research Council, Food Allergy Research and Education, Asthma UK, Immune Tolerance Network/National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and the NIHR Biomedical Research Centre award to Guy's and St Thomas’ National Health Service Foundation Trust; consultancy fees from Thermo Scientific, Nutricia, InfoMed, Novartis and Buhlmann; consultancy fees from Allergy Therapeutics, Novartis, Iggenix and Stallergenes; and research support from Buhlmann and Thermo Scientific through a collaboration agreement with King's College London. S. Schnadt is employed by Deutscher Allergie‐ und Asthmabund e.V. (DAAB), a patient organization that has received industry support. Dr Taylor reports funding for research and industry outreach activities related to food allergens received from a consortium of more than 100 food processing companies. Dr Vlieg‐Boerstra reports grants from Nutricia Research and personal fees from Nestle, Nutricia and the Marfo Food Group. Dr Remington reports grants, personal fees, nonfinancial support from DBV Technologies and nonfinancial support from ILSI Europe, outside the submitted work and is an adjunct faculty member of the University of Nebraska. The other authors have no relevant conflicts of interest to declare.

PY - 2022/6

Y1 - 2022/6

KW - anaphylaxis

KW - eliciting dose

KW - food allergy

KW - precautionary allergen labelling

KW - reference dose

KW - thresholds

UR - http://www.scopus.com/inward/record.url?scp=85131268998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131268998&partnerID=8YFLogxK

U2 - 10.1111/all.15202

DO - 10.1111/all.15202

M3 - Editorial

C2 - 34967036

AN - SCOPUS:85131268998

SN - 0105-4538

VL - 77

SP - 1661

EP - 1666

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 6

ER -